- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
PET imaging of glucose metabolism, neuroinflammation and demyelination in the lysolecithin rat model for multiple sclerosis
-
- Daniele de Paula Faria
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, The Netherlands
-
- Erik FJ de Vries
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, The Netherlands
-
- Jurgen WA Sijbesma
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, The Netherlands
-
- Carlos A Buchpiguel
- Center of Nuclear Medicine, University of São Paulo, University of São Paulo Medical School, Brazil
-
- Rudi AJO Dierckx
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, The Netherlands
-
- Sjef CVM Copray
- Department of Neuroscience, University of Groningen, University Medical Center Groningen, The Netherlands
Search this article
Description
<jats:sec><jats:title>Background:</jats:title><jats:p> Injection of lysolecithin in the central nervous system results in demyelination accompanied by local activation of microglia and recruitment of monocytes. Positron-emission tomography (PET) imaging, using specific tracers, may be an adequate technique to monitor these events in vivo and therefore may become a tool for monitoring disease progression in multiple sclerosis (MS) patients. </jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p> The objective of this paper is to evaluate the potential of PET imaging in monitoring local lesions, using [<jats:sup>11</jats:sup>C]MeDAS, [<jats:sup>11</jats:sup>C]PK11195 and [<jats:sup>18</jats:sup>F]FDG as PET tracers for myelin density, microglia activation and glucose metabolism, respectively. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Sprague-Dawley rats were stereotactically injected with either 1% lysolecithin or saline in the corpus callosum and striatum of the right brain hemisphere. PET imaging was performed three days, one week and four weeks after injection. Animals were terminated after PET imaging and the brains were explanted for (immuno)histochemical analysis. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> PET imaging was able to detect local demyelination induced by lysolecithin in the corpus callosum and striatum with [<jats:sup>11</jats:sup>C]MeDAS and concomitant microglia activation and monocyte recruitment with [<jats:sup>11</jats:sup>C]PK11195. [<jats:sup>18</jats:sup>F]FDG imaging demonstrated that glucose metabolism was maintained in the demyelinated lesions. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> PET imaging with multiple tracers allows simultaneous in vivo monitoring of myelin density, neuroinflammation and brain metabolism in small MS-like lesions, indicating its potential to monitor disease progression in MS patients. </jats:p></jats:sec>
Journal
-
- Multiple Sclerosis Journal
-
Multiple Sclerosis Journal 20 (11), 1443-1452, 2014-03-12
SAGE Publications
- Tweet
Details 詳細情報について
-
- CRID
- 1363107368376227712
-
- ISSN
- 14770970
- 13524585
-
- Data Source
-
- Crossref